A0A6D2Y7Y2 (A0A6D2Y7Y2_PANTR) Pan troglodytes (Chimpanzee)

Cellular tumor antigen p53 UniProtKBInterProInteractive Modelling

393 aa; Sequence (Fasta) ; 4 identical sequences: Homo sapiens: P04637, K7PPA8; Pan troglodytes: H2QC53; Pan paniscus: A0A2R9A5P4

Available Structures

281 Experimental Structures

DescriptionPDB IDOligo-stateRangeSeq id (%)Ligands
Structure of the p53/RNA polymerase II assembly Heteromer
O15514; P04637; P19387; P19388; P24928; P30876; P36954; P52434; P52435; P53803; P61218; P62487; P62875;
12-351
100.0MG;ZN;
Cryo-EM structure of p300-p53 protein complex Heteromer
P04637; Q09472;
92-356
100.0
Monomeric E6AP-E6-p53 ternary complex Heteromer
P03126; P04637; Q05086;
91-292
100ZN;
Dimeric ternary structure of E6AP-E6-p53 Heteromer
P03126; P04637; Q05086;
91-292
100ZN;
Crystal structure of a complex between the DNA-binding domain of p53 and the carboxyl-terminal cons… Heteromer
P04637; Q8WUF5;
91-291
100ZN;
p53 DNA binding domain in complex with Nb139 Heteromer
P04637;
92-290
100ZN;
Crystal structure of the HPV16 E6/E6AP/p53 ternary complex at 2.25 A resolution Heteromer
P03126; P04637; P0AEX9; Q05086;
94-292
100GLC;PEG;ZN;EDO;
The crystal structure of p53 DNA binding domain and PUMA complex Heteromer
P04637; Q9BXH1;
92-290
100ZN;
Structure of p53 DNA-binding domain and ZNF568 KRAB domain complex Heteromer
P04637; Q3ZCX4;
94-292
100ZN;
Crystal structure of p53 DBD domain in complex with azurin Heteromer
P00282; P04637;
92-289
100NA;ZN;K;PO4;
Crystal structure of the BRCT domains of human 53BP1 bound to the p53 tumor supressor Heteromer
P04637; Q12888;
95-292
99.47ZN;SO4;
Crystal structure of the BRCT domains of 53BP1 in complex with p53 and H2AX-pSer139 (gammaH2AX) Heteromer
P04637; Q12888;
96-293
100.0ZN;
The Structure of the Oncoprotein SV40 Large T Antigen and p53 Tumor Suppressor Complex Heteromer
P03070; P04637;
92-289
10012×ZN;
Cryo-EM structure of the nucleosome in complex with p53 DNA-binding domain Heteromer
P04637; P04908; P06899; P62805; P68431;
94-291
100
Cryo-EM structure of the nucleosome in complex with p53 Heteromer
P04637; P04908; P06899; P62805; P68431;
94-291
100
Crystal Structure of the 53bp1 BRCT Region Complexed to Tumor Suppressor P53 Heteromer
P04637; Q12888;
95-289
100ZN;
Solution Structure of the Complex Between BCL-xL and the p53 Core Domain determined with PRE restra… Heteromer
P04637; Q07817;
96-290
100ZN;
Crystal structure of p53/BCL2 fusion complex(complex3) Heteromer
P04637; P10415;
95-288
100ZN;
Crystal structure of p53/BCL2 fusion complex (complex 2) Heteromer
P04637; P10415;
95-288
100ZN;
Crystal structure of p53/BCL2 fusion complex (complex 1) Heteromer
P04637; P10415;
95-288
100ZN;
HPV16 E6-E6AP-p53 complex Heteromer
P03126; P04637; Q05086;
98-290
100.0ZN;
P53-53BP2 COMPLEX Heteromer
P04637; Q13625;
97-287
100ZN;
Structure of CBP nuclear coactivator binding domain in complex with p53 TAD Heteromer
P04637; P45481;
13-61
100
HMGB1-facilitated p53 DNA binding occurs via HMG-box/p53 transactivation domain interaction and is … Heteromer
P04637; P09429;
14-60
100
Structural Basis for the Regulation of p53 Function by p300 Heteromer
P04637; Q09472;
1-39
100
Transactivation domain of p53 in complex with S100P, using annexin A2 as crystallization chaperone Heteromer
P04637; P07355; P25815;
19-55
100.0GOL;CA;
Crystal Structure of a Designed Protein Heterocatenane Heteromer
P04637; P42212;
322-356
88.57
Characterization of the p300 Taz2-p53 TAD2 Complex and Comparison with the p300 Taz2-p53 TAD1 Compl… Heteromer
P04637; Q09472;
35-59
100
p53N (fragment 33-60) bound to RPA70N Heteromer
P04637; P27694;
33-56
100
Solution structure of the complex between p53 transactivation domain 2 and TFIIH p62 PH domain Heteromer
P04637; P32780;
41-62
100
SOLUTION STRUCTURE OF THE C-TERMINAL NEGATIVE REGULATORY DOMAIN OF P53 IN A COMPLEX WITH CA2+-BOUND… Heteromer
P04631; P04637;
367-388
100CA;
NMR Structure of CBP Bromodomain in complex with p53 peptide Heteromer
P04637; Q92793;
367-386
100
Solution structure of 53BP1 tandem Tudor domains in complex with a p53K370me2 peptide Heteromer
P04637; Q12888;
363-377
100
Mdmx-p53 Heteromer
O15151; P04637;
15-29
100
Crystal Structure Analysis of Zebra Fish MDMX Heteromer
P04637; Q7ZUW7;
16-29
78.57SO4;
Crystal Structure Analysis of Zebra Fish MDMX Heteromer
P04637; Q7ZUW7;
16-29
85.71
NMR structure of the complex between the PH domain of the Tfb1 subunit from TFIIH and the activatio… Heteromer
P04637; P32776;
45-58
100
Sir2-p53 peptide-nicotinamide Heteromer
P04637; Q9WYW0;
373-385
100ZN;NCA;
The Structural Basis for Sirtuin Substrate Affinity Heteromer
P04637; Q9WYW0;
373-385
100ZN;
Structure of Sir2Tm bound to a propionylated peptide Heteromer
P04637; Q9WYW0;
373-385
92.31ZN;
MDM2 BOUND TO THE TRANSACTIVATION DOMAIN OF P53 Heteromer
P04637; Q00987;
17-29
100
Crystal structure of 14-3-3sigma and a p53 C-terminal 12-mer synthetic phosphopeptide Heteromer
P04637; P31947;
382-393
100CA;MG;
Fragment AZ-003 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
382-393
100MG;CL;GOL;K48;
Fragment AZ-010 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
382-393
100KM8;
Fragment AZ-009 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
382-393
100KLZ;MG;
Fragment AZ-015 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
382-393
100MG;CL;GOL;K6B;
Fragment AZ-024 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
382-393
100MG;CL;K7Q;
Fragment AZ-025 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
382-393
100MG;CL;K7N;
Fragment AZ-026 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
382-393
100MG;CL;K92;
Fragment AZ-011 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
382-393
100MG;CL;LFB;
Fragment AZ-017 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
382-393
100MG;CL;LFQ;
Fragment AZ-020 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
382-393
100K65;
Fragment AZ-002 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
382-393
100KLE;CA;MG;
Fragment AZ-007 binding at a primary and secondary binding site of the the p53pT387/14-3-3 sigma co… Heteromer
P04637; P31947;
382-393
100KLB;CA;MG;
Fragment AZ-004 binding at a primary and secondary site in a p53pT387/14-3-3 complex Heteromer
P04637; P31947;
382-393
100L1T;CA;
Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain Heteromer
P04637; Q7ZUW7;
17-28
100
Crystal structure of 14-3-3sigma and a p53 C-terminal 12-mer synthetic phosphopeptide Heteromer
P04637; P31947;
382-393
100CL;MG;
Fragment AZ-018 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
382-393
100K5Z;CA;
Fragment AZ-023 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
382-393
100MG;CL;K6T;
Fragment AZ-022 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
382-393
100MG;CL;GOL;K6Z;
Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain Heteromer
O15151; P04637;
17-28
100
Fragment AZ-013 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
382-393
100MG;CL;LJW;
Fragment AZ-001 binding at the p53pT387/14-3-3 sigma interface and additional sites Heteromer
P04637; P31947;
382-393
100MG;CL;KTW;GOL;CA;
Solution structure of 53BP1 tandem Tudor domains in complex with a p53K382me2 peptide Heteromer
P04637; Q12888;
376-387
100
Sir2-deacetylated peptide (from enzymatic turnover in crystal) Heteromer
P04637; Q9WYW0;
375-385
100ZN;NCA;OAD;
Molecular basis for the inhibition of p53 by Mdmx Heteromer
P04637; Q7ZUW7;
17-27
100
XENOPUS LAEVIS MDM2 BOUND TO THE TRANSACTIVATION DOMAIN OF HUMAN P53 Heteromer
P04637; P56273;
17-27
100
Molecular basis for the inhibition of p53 by Mdmx Heteromer
P04637; Q7ZUW7;
17-27
100
Crystal Structure of an MDM2/P53 Peptide Complex Heteromer
P04637; Q00987;
17-27
100SO4;
Fragment AZ-012 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
384-393
100CL;LF5;
Crystal structure of the 53BP1 tandem tudor domain in complex with p53K381acK382me2 Heteromer
P04637; Q12888;
377-386
100
Fragment AZ-021 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
382-391
100MG;CL;GOL;K6W;
Fragment AZ-006 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
382-391
100MG;CL;GOL;JT2;
Fragment AZ-019 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
382-391
100MG;CL;GOL;KDK;
Structure of a Sir2 enzyme bound to an acetylated p53 peptide Heteromer
O30124; P04637;
379-387
100ZN;MES;
Crystal Structure of human O-GlcNAcase in complex with glycopeptide p53 Heteromer
O60502; P04637;
146-154
100NAG;
CDK2/CyclinA in complex with an 11-residue recruitment peptide from p53 Heteromer
P04637; P20248; P24941;
378-386
100
Complex of HLA-A2, a class I MHC, with a p53 peptide Heteromer
A0A140T913; P04637; P61769;
168-176
100
Complex of HLA-A2, a class I MHC, with a p53 peptide Heteromer
A0A140T913; P04637; P61769;
168-176
88.89
T cell receptor-p53-HLA-A2 complex Heteromer
A0A140T913; P04637; P61769;
168-176
88.89
T cell receptor-p53-HLA-A2 complex Heteromer
A0A140T913; P04637; P61769;
168-176
88.89
T cell receptor-p53-HLA-A2 complex Heteromer
A0A140T913; P04637; P61769;
168-176
88.89
Neoantigen p53R175H-specific TCR 6-11 binds to p53R175H-HLA-A2 Heteromer
P04439; P04637; P61769;
168-176
88.89
Structure of the antibody fragment H2 in complex with HLA-A*02:01/p53R175H Heteromer
A0A140T913; P04637; P61769;
168-176
88.89
Fragment AZ-014 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
384-391
100MG;CL;K6N;
Fragment AZ-016 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
383-390
100MG;CL;K8W;
Structure of Leishmania infantum Silent Information Regulator 2 related protein 1 (LiSIR2rp1) in co… Heteromer
A0A6L0XH39; P04637;
379-386
100ZN;
Sir2 H116Y mutant-p53 peptide-NAD Heteromer
P04637; Q9WYW0;
378-385
100ZN;NAD;
Sir2-p53 peptide-NAD+ Heteromer
P04637; Q9WYW0;
378-385
100ZN;NAD;
Structure of SMYD2 in complex with p53 and SAH Heteromer
P04637; Q9NRG4;
368-375
100GOL;SAH;ZN;
CpOGA D298N in complex with p53-derived O-GlcNAc peptide Heteromer
P04637; Q0TR53;
145-152
10018×CD;NAG;
Binary complex of 14-3-3 sigma and p53 pT387-peptide Heteromer
P04637; P31947;
385-391
100MG;CL;GOL;
The Crystal Structure of the N-terminal domain of HAUSP/USP7 complexed with p53 peptide 364-367 Heteromer
P04637; Q93009;
361-367
85.71
Fragment AZ-005 binding at the p53pT387/14-3-3 sigma interface Heteromer
P04637; P31947;
385-391
100MG;CA;KM2;
SIR2 COMPLEX STRUCTURE MIXTURE OF EX-527 INHIBITOR AND REACTION PRODUCTS OR OF REACTION SUBSTRATES … Heteromer
P04637; Q9WYW0;
379-385
100OCZ;NAD;OAD;ZN;EDO;
The Structural basis for Sirtuin Substrate affinity Heteromer
P04637; Q9WYW0;
378-384
100ZN;
SIRT1/Activator/Substrate Complex Heteromer
P04637; Q96EB6;
379-385
85.71ZN;CNA;4TQ;GOL;
ATM(Q2971A) dimeric C-terminal region activated by oxidative stress in complex with Mg AMP-PNP and … Heteromer
P04637; Q13315;
12-18
100ANP;MG;ZN;
ATM(Q2971A) activated by oxidative stress in complex with Mg AMP-PNP and p53 peptide Heteromer
P04637; Q13315;
12-18
100ANP;MG;ZN;
Crystal structure of a ternary complex of the methyltransferase SET9 (also known as SET7/9) with a … Heteromer
P04637; Q8WTS6;
369-374
100SAH;
Sir2 H116A-deacetylated p53 peptide-3'-o-acetyl ADP ribose Heteromer
P04637; Q9WYW0;
380-385
100ZN;APR;3OD;
The Crystal Structure of the N-terminal domain of HAUSP/USP7 complexed with p53 peptide 359-362 Heteromer
P04637; Q93009;
358-363
100
CRYSTAL STRUCTURE OF SIR2 IN COMPLEX WITH THE INHIBITOR EX-527, 2'-O-ACETYL-ADP-RIBOSE AND DEACETYL… Heteromer
P04637; Q9WYW0;
380-384
100OCZ;OAD;ZN;
Crystal structure of HDAC8-substrate complex Heteromer
P04637; Q9BY41;
379-382
100K;ZN;
Crystal structure of SIRT3 in complex with acetyl p53 peptide coupled with 4-amino-7-methylcoumarin Heteromer
P04637; Q9NTG7;
379-382
100ZN;
Crystal structure of the 3-MBT domain from human L3MBTL1 in complex with p53K382me1 Heteromer
P04637; Q9Y468;
382-382
100
Structure of the amyloid-forming segment LTIITLE from p53 (residues 252-258)homo-6-mer252-258
100
Structure of the amyloid-forming segment TIITLE from p53 (residues 253-258)homo-6-mer253-258
100ZN;
An induced fit mechanism regulates p53 DNA binding kinetics to confer sequence specificityhomo-4-mer94-356
93.47ZN;
Crystal structure of a multidomain human p53 tetramer bound to the natural CDKN1A(p21) p53-response…homo-4-mer94-356
93.47ZN;
Crystal structure of a polypeptide p53 mutant bound to DNAhomo-4-mer94-356
92.46ZN;
An induced fit mechanism regulates p53 DNA binding kinetics to confer sequence specificityhomo-4-mer96-354
93.4ZN;
Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidi…homo-4-mer94-293
99.49ZN;QN8;QNN; 48×FMT;ACT;EDO;
New Insights into the Role of DNA Shape on Its Recognition by p53 Proteins (complex p53DBD-LHG1)homo-4-mer94-293
100ZN; 12×EDO;FOR;
New Insights into the Role of DNA Shape on Its Recognition by p53 Proteins (complex p53DBD-p53R2)homo-4-mer94-293
100.0ZN;
New Insights into the Role of DNA Shape on Its Recognition by p53 Proteins (complex p53DBD-GADD45)homo-4-mer94-293
100.0ZN;PEG;
New Insights into the Role of DNA Shape on Its Recognition by p53 Proteins (complex p53DBD-LWC1)homo-4-mer94-293
100ZN; 20×EDO;ACT;
Structural Basis of DNA Recognition by p53 Tetramers (complex I)homo-4-mer94-293
100ZN;
Structural Basis of DNA Recognition by p53 Tetramers (complex III)homo-4-mer94-293
100ZN;
Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidi…homo-4-mer94-293
99.49ZN;FMT;
Crystal structure of p53 core domain in complex with DNAhomo-4-mer92-291
100ZN;
Crystal structure of the p53 core domain bound to a full consensus site as a self-assembled tetramerhomo-4-mer92-291
100ZN;
Human p53 core domain with hot spot mutation R273C and second-site suppressor mutation T284R in seq…homo-4-mer94-292
98.98ZN; 16×EDO;ACT;
New Insights into the Role of DNA Shape on Its Recognition by p53 Proteins (complex p53DBD-LWC2)homo-4-mer94-292
100ZN;FOR;
New Insights into the Role of DNA Shape on Its Recognition by p53 Proteins (complex p53DBD-AGG-HG)homo-4-mer94-292
100ZN; 14×EDO;
Structural Basis of DNA Recognition by p53 Tetramers (complex II)homo-4-mer94-292
100ZN;
Structural Basis of DNA Recognition by p53 Tetramers (complex IV)homo-4-mer94-292
100ZN;
Diversity in DNA recognition by p53 revealed by crystal structures with Hoogsteen base pairs (p53-D…homo-4-mer95-292
100.0ZN;IOD;
Human p53 core domain with hot spot mutation R282W in complex with the natural CDKN1A(p21) p53-resp…homo-4-mer95-292
99.5ARS;ZN;
Lysine 120-acetylated P53 DNA binding domain in a complex with the BAX response element.homo-4-mer94-291
100ZN;
New Insights into the Role of DNA Shape on Its Recognition by p53 Proteins (complex p53DBD-LHG2)homo-4-mer95-291
100ZN; 12×EDO;
Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidi…homo-4-mer95-290
100.0ZN;QN8;ACT;QNN;
Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidi…homo-4-mer95-289
99.48ZN;QNN;EDO;QN8;PEG;
Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidi…homo-4-mer96-289
99.48ZN;QNN;EDO;ACT;PEG;
Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidi…homo-4-mer97-289
99.47ZN;QN8;QNN;EDO;PEG;
Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidi…homo-4-mer96-288
99.47ZN;QN8;QNN;
HIGH-RESOLUTION SOLUTION STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI-DIMENSIONAL NMRhomo-4-mer319-360
100
HIGH RESOLUTION SOLUTION NMR STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI-DIMENSIONAL NM…homo-4-mer319-360
100
HIGH-RESOLUTION SOLUTION STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI-DIMENSIONAL NMRhomo-4-mer319-360
100
HIGH RESOLUTION SOLUTION NMR STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI-DIMENSIONAL NM…homo-4-mer319-360
100
HIGH RESOLUTION SOLUTION NMR STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI-DIMENSIONAL NM…homo-4-mer319-360
100
HIGH RESOLUTION SOLUTION NMR STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI-DIMENSIONAL NM…homo-4-mer319-360
100
HIGH RESOLUTION SOLUTION NMR STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI-DIMENSIONAL NM…homo-4-mer319-360
100
CRYSTAL STRUCTURE OF P53 TETRAMERIZATION DOMAINhomo-4-mer325-356
100
Crystal structure of the human p53 tetramerization domainhomo-4-mer326-356
100
P53 TETRAMERIZATION DOMAIN CRYSTAL STRUCTUREhomo-4-mer326-356
100
NMR SOLUTION STRUCTURE OF THE TETRAMERIC MINIMUM TRANSFORMING DOMAIN OF P53homo-4-mer325-355
100
p53 tetramerization domain wild typehomo-4-mer326-356
100
p53 tetramerization domain mutant T329F Q331Khomo-4-mer326-356
93.55
NMR SOLUTION STRUCTURE OF THE TETRAMERIC MINIMUM TRANSFORMING DOMAIN OF P53homo-4-mer325-355
100
p53 tetramerization domain mutant Y327S T329G Q331Ghomo-4-mer326-356
90.32
Disulfide-linked, antiparallel p53-derived peptide dimer (CV1)homo-4-mer17-30
50.0SO4;
P53 CORE DOMAIN IN COMPLEX WITH DNAhomo-3-mer94-289
100ZN;
TUMOR SUPPRESSOR P53 COMPLEXED WITH DNAhomo-3-mer94-289
100ZN;
Wild type P53 dimer structure from human cancer cellshomo-2-mer1-393
100
An induced fit mechanism regulates p53 DNA binding kinetics to confer sequence specificityhomo-2-mer94-356
93.43ZN;
Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidi…homo-2-mer94-293
100.0ZN;QN8;QNN;FMT;
Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidi…homo-2-mer94-293
100.0ZN;ACT;EDO;QN8;QNN;FMT;
Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidi…homo-2-mer94-293
99.47ZN;QN8;QNN;PG4;EDO;
Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidi…homo-2-mer94-293
100.0ZN;QNN;QN8;
Diversity in DNA recognition by p53 revealed by crystal structures with Hoogsteen base pairs (p53-D…homo-2-mer94-293
98.98ZN;
Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidi…homo-2-mer94-293
99.49ZN;FMT;
Human p53 core domain with hot spot mutation R273H and second-site suppressor mutation T284R in seq…homo-2-mer94-293
98.98ZN; 34×EDO;
Diversity in DNA recognition by p53 revealed by crystal structures with Hoogsteen base pairs (p53-D…homo-2-mer94-293
100.0ZN;EDO;
Lysine 120-acetylated P53 DNA binding domain in a complex with DNA.homo-2-mer94-293
100ZN;
Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidi…homo-2-mer94-293
98.98ZN;QNN;QN8;FMT;
Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidi…homo-2-mer94-293
99.5ZN;EDO;PEG;
Human p53 core domain with hot spot mutation R273C and second-site suppressor mutation S240R in seq…homo-2-mer94-293
98.9814×EDO;ZN;
Human p53 core domain with hot spot mutation R249S and second site suppressor mutation H168R in seq…homo-2-mer95-291
98.98ZN;
NMR SOLUTION STRUCTURE OF DESIGNED P53 DIMERhomo-2-mer324-357
94.12
SOLUTION STRUCTURE DETERMINATION OF A P53 MUTANT DIMERIZATION DOMAIN, NMR, MINIMIZED AVERAGE STRUCT…homo-2-mer326-354
89.66
P53 monomer structuremonomer1-393
100
p53 charged coremonomer89-292
97.55GOL;ZN;
Solution structure of human p53 DNA binding domain.monomer94-297
100ZN;
Human p53 core domain with germline hot spot mutation M133T in complex with the natural PIG3 p53-re…monomer94-293
99.48ARS;ZN;
Crystal structure of p53DBD(R282Q) at 1.54-angstrom Resolutionmonomer94-292
99.5ZN;
Crystal structure of the DNA-binding domain of human p53 with extended N terminusmonomer91-289
100ZN;
The Crystal Structure of p53 from Biortus.monomer94-292
97.49PO4;ZN;EDO;
p53 cancer mutant Y220C in complex with small-molecule stabilizer PK9318monomer95-292
97.47ZN;EXQ;EDO;
p53-Y220C Core Domain in Complex with a Bromo-trifluoro-pyrazole-aminemonomer94-291
97.47LE9;EPE;ZN;PEG;
Human p53 core domain with hot spot mutation R273H (form II)monomer94-291
99.5ZN;DTT;EDO;
Human p53 Core Domain Mutant V157F/N235K/N239Ymonomer94-291
98.48ZN;
p53 cancer mutant Y220Cmonomer96-292
97.46EDO;ZN;
p53 cancer mutant Y220C in complex with small-molecule stabilizer PK9320monomer96-292
97.46ZN;EXN;EDO;
p53 cancer mutant Y220C in complex with small-molecule stabilizer PK9327monomer96-292
97.46ZN;EYE;
Crystal structure of the p53 (Y107H) core domain orthorhombic P formmonomer95-291
99.49ZN;
p53 cancer mutant Y220C im complex with compound MB577monomer96-292
97.46ZN;9GT;
p53 cancer mutant Y220C in complex with compound MB184monomer96-292
97.46ZN;9GZ;
Crystal structure of the p53 cancer mutant Y220C in complex with a difluorinated derivative of the …monomer96-292
97.46ZN;O83;
p53 cancer mutant Y220C in complex with compound MB481monomer96-292
97.46ZN;9GW;
Structure of p53 cancer mutant Y234Cmonomer96-292
97.46ZN;GOL;
p53 cancer mutant Y220S in complex with small-molecule stabilizer PK9301monomer96-292
97.46ZN;LEB;EDO;
p53 cancer mutant Y220C in complex with compound MB84monomer96-292
97.46ZN;9H2;GOL;
p53 cancer mutant Y220Hmonomer96-292
97.46ZN;EDO;GOL;EPE;
Human p53 core domain with hot spot mutation R273H and second-site suppressor mutation S240Rmonomer94-290
98.98ZN;EDO;
p53 cancer mutant Y220C in complex with iodophenol-based small-molecule stabilizer JC694monomer96-292
97.46KV0;ZN;
p53 cancer mutant Y220C in complex with iodophenol-based small-molecule stabilizer JC769monomer96-292
97.46KVA;EDO;ZN;
Structure of the p53 cancer mutant Y220C with bound 3-bromo-5-(trifluoromethyl)benzene-1,2-diaminemonomer96-292
97.46UFV;ZN;
Structure of the p53 core domain mutant Y220C bound to the stabilizing small molecule PhiKan5086monomer96-292
97.46P86;ZN;
p53 cancer mutant Y220C in complex with small-molecule stabilizer PK9323monomer95-291
97.46ZN;LEK;EDO;
Structure of p53 cancer mutant Y220C with arylation at Cys182 and Cys277monomer96-292
97.46ZN;A1IH3;
Structure of the p53 core domain mutant Y220C bound to the stabilizing small molecule PhiKan5116monomer96-292
97.46ZN;NXG;
Structure of p53 cancer mutant Y163Cmonomer94-290
97.46ZN;EDO;MLI;
p53 cancer mutant Y220C in complex with compound MB539monomer96-291
97.45ZN;9GN;
Structure of the p53 cancer mutant Y220C in complex with small-molecule stabilizer PK9328monomer96-291
97.45ZN;EXQ;
p53 cancer mutant Y220C in complex with compound MB487monomer96-291
97.45ZN;9GK;
p53 cancer mutant Y220C in complex with compound MB582monomer96-291
97.45ZN;9GQ;
Structure of the p53 cancer Y220C bound to the stabilizing small molecule PhiKan5211monomer96-291
97.45ZN;KMN;
p53 cancer mutant Y220C in complex with compound MB710monomer96-291
97.45ZN;9GH;EDO;
p53 cancer mutant Y220C in complex with small-molecule stabilizer PK9324monomer96-291
97.45ZN;EYB;
p53 cancer mutant Y220C in complex with compound MB240monomer96-291
97.45ZN;9H5;
Structure of the p53 core domain mutant Y220C bound to the stabilizing small molecule PhiKan5174monomer96-291
97.45P74;ZN;
Crystal structure of the p53 cancer mutant Y220C in complex with a trifluorinated derivative of the…monomer96-291
97.45ZN;O80;
Structure of the p53 core domain mutant Y220C bound to the stabilizing small molecule PhiKan5176monomer96-291
97.45P51;ZN;
p53 cancer mutant Y220Smonomer96-291
97.45ZN;EDO;
Structure of p53 cancer mutant Y205Cmonomer96-291
97.96ZN;TLA;EDO;
p53 cancer mutant Y220C in complex with small-molecule stabilizer PK9284monomer96-291
97.45EY2;ZN;
Crystal structure of p53 Y220C covalently bound to indole KG6monomer94-289
95.26ZN;SO4;R4F;
Structure of p53 cancer mutant Y126Cmonomer96-291
97.31ZN;EDO;
Human p53 core domain with hot spot mutation R273H and second-site suppressor mutation T284Rmonomer95-290
98.98ZN;
Crystal structure of p53 Y220C covalently bound to azaindole KG13monomer94-289
95.41R50;SO4;ZN;MG;
HUMAN P53 CORE DOMAIN MUTANT M133L-V203A-Y236F-N239Y-T253I-N268Dmonomer96-291
96.94ZN;
p53 cancer mutant Y220S in complex with small-molecule stabilizer PK9323monomer96-291
97.45ZN;LEK;
Crystal structure of p53 Y220C covalently bound to indole KG10monomer94-289
95.41SO4;ZN;MG;R4R;
Structure of p53 cancer mutant Y236Cmonomer96-291
97.45ZN;TLA;EDO;
Crystal structure of p53 Y220C covalently bound to carbazole KG3monomer94-289
95.41ZN;R3R;
The Crystal Structure of p53/BCL-xL fusion complex from Biortus.monomer95-290
100.0ZN;
Structure of the p53 cancer mutant Y220C with bound small molecule PhiKan7099monomer96-290
97.44ZN;GOL;GOH;
Structure of the p53 core domain mutant Y220C bound to the small molecule PhiKan7242monomer96-290
97.44ZN;QC5;
Structure of the p53 cancer mutant Y220C with bound small molecule 7- ethyl-3-(piperidin-4-yl)-1H-i…monomer96-290
97.44ZN;PEG;92O;
Crystal structure of the p53 cancer mutant Y220C in complex with a monofluorinated derivative of th…monomer96-290
97.44ZN;O82;
p53 cancer mutant Y220C with Cys182 alkylationmonomer96-290
97.44ZN;6SM;
Structure of the p53 core domain mutant Y220C bound to the stabilizing small molecule PhiKan5196monomer96-290
97.44P96;ZN;
Structure of p53 cancer mutant Y220C (hexagonal crystal form)monomer97-291
97.31ZN;EDO;MG;CL;
Structure of the p53 cancer mutant Y220C in complex with 2-hydroxy-3, 5-diiodo-4-(1H-pyrrol-1-yl)be…monomer96-290
97.44Y0V;ZN;
Structure of the p53 core domain mutant Y220C bound to the stabilizing small-molecule drug PhiKan083monomer96-290
97.44ZN;
STRUCTURE OF THE P53 CORE DOMAIN MUTANT Y220C BOUND TO A 2-amino substituted benzothiazole scaffoldmonomer96-290
97.44ZN;
Structure of the p53 cancer mutant Y220C with bound small-molecule stabilizer PhiKan5149monomer96-290
97.44ZN;UL7;
Human p53 core domain mutant M133L-V203A-Y220C-N239Y-N268Dmonomer96-290
97.44ZN;
Human p53 core domain mutant M133L-V203A-N239Y-G245S-N268Dmonomer95-289
97.4ZN;CA;
Structure of the p53 core domain mutant Y220C bound to the stabilizing small molecule PhiKan784monomer96-290
97.44P84;ZN;
Structure of the p53 cancer mutant Y220C with bound small molecule PhiKan883monomer96-290
97.44FY8;GOL;ZN;
Structure of the p53 cancer mutant Y220C in complex with an indole- based small moleculemonomer96-290
97.44ZN;
Human p53 core domain mutant M133L-V203A-N239Y-N268D-F270Lmonomer96-290
97.44ZN;
Human p53 core domain mutant M133L-V203A-N239Y-N268D-R273Cmonomer96-290
97.44ZN;SO4;
Human p53 core domain mutant M133L-V143A-V203A-N239Y-N268Dmonomer96-290
97.44ZN;
human p53 core domain mutant T123A-M133L-H168R-V203A-N239Y-R249S- N268Dmonomer96-290
96.22ZN;
human p53 core domain mutant M133L-H168R-V203A-N239Y-R249S-N268Dmonomer96-290
96.76ZN;
STRUCTURE OF THE P53 CORE DOMAIN MUTANT Y220C BOUND TO 4-(trifluoromethyl)benzene-1,2-diaminemonomer96-290
97.41ZN;
Crystal structure of the human p53 core domain mutant M133L/V203A/N239Y/N268D at 1.9 A resolution.monomer96-290
97.95ZN;
Human p53 core domain with hot spot mutation R249S and second-site suppressor mutations H168R and T…monomer96-290
98.4ZN;
human p53 core domain mutant M133L-H168R-V203A-N239Y-N268Dmonomer97-291
97.81ZN;
human p53 core domain mutant M133L-V203A-N239Y-N268D-R273Hmonomer96-290
97.44ZN;SO4;
STRUCTURE OF THE P53 CORE DOMAIN MUTANT Y220C BOUND TO 5,6-dimethoxy- 2-methylbenzothiazolemonomer96-290
97.44ZN;
Human p53 core domain with hot spot mutation R249S (III)monomer94-288
99.48ZN;
Human p53 Core Domain Mutant V157Fmonomer96-289
99.48ZN;
Human p53 Core Domain Mutant N239Ymonomer96-289
99.48ZN;
human p53 core domain mutant M133L-V203A-N239Y-R249S-N268Dmonomer97-290
97.31ZN;
Arsenic-bound p53 DNA-binding domain mutant V272Mmonomer96-289
99.48ARS;ZN;
Human p53 core domain in the absence of DNAmonomer96-289
100ZN;
Crystal structure of p53/BCL-xL fusion complexmonomer96-289
100ZN;
Human p53 Core Domain Mutant N235Kmonomer96-289
99.48ZN;
Crystal complex of p53-V272M and antimony ionmonomer96-289
99.48ZN;SB;
Crystal structure of a human mutant p53monomer96-288
92.23ZN;
Human p53 core domain mutant M133L-V203A-N239Y-N268D-R282Wmonomer96-288
97.34ZN;
Human p53 core domain with hot spot mutation R249S (II)monomer96-288
99.45ZN;
Arsenic-bound p53 DNA-binding domain mutant R249Smonomer97-289
99.48GOL;ARS;ZN;
Human p53 core domain with hot spot mutation R273H (form I)monomer96-288
99.48ZN;
Structure of Lys120-acetylated p53 core domainmonomer96-288
100.0ZN;
Human p53 core domain with hot spot mutation R273C and second-site suppressor mutation T284Rmonomer96-288
98.96ZN;EDO;
Mutant R280K of human P53monomer97-289
99.48ZN;
Arsenic-bound p53 DNA-binding domain mutant G245Smonomer97-289
99.48ARS;ZN;
Crystal structure of the p53 (Y107H) core domain monoclinic P formmonomer97-289
99.48ZN;
Human p53 core domain with hot spot mutation R249S (I)monomer97-288
99.44ZN;
Human p53 core domain with hot spot mutation R273Cmonomer97-288
99.48ZN;ACT;
Human p53 core domain with hot spot mutation R249S and second-site suppressor mutation H168Rmonomer97-287
98.9ZN;
Solution Structure of p53TAD-TAZ1monomer1-69
100ZN;
Solution Structure of TAZ2-p53TADmonomer2-61
100ZN;
Structure determination of the transactivation domain of p53 in complex with S100A4 using annexin A…monomer17-56
100.0GOL; 10×CA;
Solution Structure of TAZ2-p53AD2monomer37-61
100ZN;
The crystal structure of p53p peptide fragment in complex with the N-terminal domain of MdmXmonomer23-29
100.0O4B;MG;

4 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
3q05.1.Amonomer0.6894-355
ZN;92.70
8f2h.1.Amonomer0.681-393
100.00
3q01.1.Bmonomer0.6794-356
ZN;92.70
6xre.1.Mmonomer0.6412-351
100.00